Viking Therapeutics Stock Surges 36% on VK2735 Maintenance Data

Q: Why is VKTX stock up today?

Viking Therapeutics (VKTX) stock jumped 36% to $40.85 on Tuesday after its VK2735 obesity drug showed patients kept up to 97% of weight lost after switching from weekly to monthly or biweekly injections.

Viking Therapeutics IR2 min read6 sources

Why is VKTX stock up today?

Key numbers

VKTX close Sep 22	$40.85+35.7% (+$10.74); early reports cited ~27% intraday [3]
Weight kept, biweekly best cohort	97%+36 pp vs placebo 61% (p<0.0001)
Weight kept, monthly best cohort	90%+29 pp vs placebo 61% (p=0.0002)
Induction weight loss at 21 weeks	16–19%vs ~0% placebo (p<0.0001)
Week-33 weight loss, continued weekly 17.5 mg	21.7%placebo-adjusted; no plateau through week 33
Phase 3 VANQUISH patients enrolled	~5,500VANQUISH-1 ~4,500 + VANQUISH-2 ~1,000

What happened

Viking Therapeutics (VKTX) stock jumped 36% to $40.85 on Tuesday after its VK2735 obesity drug showed patients kept up to 97% of weight lost after switching from weekly to monthly or biweekly injections. VK2735 targets the same two hunger-regulating hormones — GLP-1 and GIP — as Eli Lilly's Zepbound and Novo Nordisk's Wegovy, and had already shown 16–19% body-weight loss after 21 weeks of once-weekly shots. In the 12-week maintenance phase, patients switching to every-other-week dosing kept 90% of their weight loss on average; monthly users kept 85%, versus only 61% for those given a dummy injection. Both Phase 3 trials — VANQUISH-1 (roughly 4,500 patients) and VANQUISH-2 (roughly 1,000) — are fully enrolled, with results expected around mid-2027.

Why it matters

Viking Therapeutics' results matter because staying on obesity drugs is the central challenge — patients who find weekly injections inconvenient often stop and regain weight. VK2735 showed it can preserve most of its weight loss with injections as infrequent as once a month, something no currently approved injectable obesity drug offers. If these results hold in Phase 3, Viking would enter the $66 billion global obesity market with a concrete convenience argument against the weekly Zepbound and Wegovy.

Who this affects

Marketbullish Medium impact: Obesity-drug investors got a fresh catalyst, lifting VKTX sharply.
Companybullish High impact: VKTX shareholders gained 36% as drug shows best-case maintenance profile.
Competitorsbearish Medium impact: Novo Nordisk and Eli Lilly face a new convenience rival from VKTX.
Industrybullish Medium impact: Monthly obesity dosing could broaden the GLP-1 drug market significantly.